- Scale. Oura is seeking to raise up to $2.2 billion in the largest health-wearable IPO in history, pricing 50 million shares at $40–$44 on a fully diluted valuation of $15.6 billion — a significant step up from its $11 billion private valuation in late 2025.
- Validation. The bookbuild attracted early anchor interest from Eli Lilly at up to $100 million and Dragoneer Investment Group at up to $300 million, providing a strategic-pharma imprimatur alongside financial backing before the roadshow had even closed.
- Timing. Oura’s debut comes in a September IPO window that defied seasonal expectations, with 2026 tracking toward the strongest IPO performance since the 2021 boom, though the volume of new issuances is running 30% below 2025 while total proceeds have surged nearly 400%.
Oura, the Finnish maker of smart health-tracking rings, opened its IPO roadshow on September 21, 2026, targeting a Nasdaq listing under the ticker OURA. The company is offering 50 million shares — 13.5 million newly issued and 36.5 million from existing shareholders — at a price range of $40 to $44 per share, with Goldman Sachs, Morgan Stanley, and J.P. Morgan as lead underwriters.
The revenue story behind the valuation
Oura’s financial filing offers a concrete case for the premium. Revenue for the nine months ended June 30, 2026 reached $1.21 billion — a 74% increase from the same period a year earlier. The company sold 4.1 million rings in that period, up from 1.8 million the prior year, and its paid subscription base reached 5 million members as of June. The company is projecting roughly $2 billion in full-year 2026 revenue.
The growth numbers are striking, but the net loss for the same nine-month period was $924 million, reflecting heavy investment in manufacturing scale, subscriber acquisition, and the health partnerships — including an expanding relationship with Eli Lilly — that underpin its long-term positioning as a clinical-grade health data platform rather than a consumer gadget.
The pharma angle
Eli Lilly’s indicated interest of up to $100 million is the most strategically significant element of the IPO structure. Lilly has been building partnerships with continuous health monitoring platforms to support its GLP-1 drug programs, where adherence tracking and metabolic data collection represent a meaningful clinical and commercial edge. An Oura tie-up would give Lilly real-world data on patients taking weight-loss drugs — data worth considerably more than the $100 million investment if the FDA begins accepting passive monitoring as a supplement to clinical trial endpoints.
Dragoneer’s indicated $300 million interest is a financial signal as much as a strategic one: the firm has backed the last three years of Oura’s private funding rounds and its willingness to anchor the public offering signals confidence in the pricing, according to the Traders Agency roadshow analysis.
Context in the 2026 IPO market
Oura’s roadshow follows the company’s formal Nasdaq filing earlier this month. The IPO is expected to price in the week of September 28, ahead of a broader pipeline that includes Altera’s confidential filing targeting $2 billion-plus in proceeds. The health-tech segment has been one of the stronger performers in the 2026 IPO window, benefiting from institutional appetite for companies with recurring subscription revenue rather than the pure-hardware profiles that struggled in the 2022 rate-shock environment.